The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

The PRIMO study: A phase 2 study of duvelisib efficacy and safety in patients with relapsed or refractory peripheral t-cell lymphoma (PTCL).

Steven M.  Horwitz

Consulting or Advisory Role - Celgene; Forty Seven; HUYA Bioscience International; Infinity Pharmaceuticals; Kyowa Hakko Kirin; Millennium; Seagen

Research Funding - ADC Therapeutics; Aileron Therapeutics; Celgene; Forty Seven; Infinity Pharmaceuticals; Kyowa Hakko Kirin; Seagen; Spectrum Pharmaceuticals; Takeda

Jasminder  Soto

Employment - Verastem

Hagop  Youssoufian

Employment - Verastem

Deborah  Lloyd

Employment - Verastem

Ngocdiep T.  Le

Employment - Verastem

Leadership - Verastem

Stock and Other Ownership Interests  - Verastem